BACKGROUND: Overt @entity99 (OHE) is a frequent complication of decompensated @entity82 . AIMS: A multicenter prospective observational study was performed to assess the most commonly recorded presenting manifestations of OHE and its associated health-care burden. METHODS: Qualifying @entity1 must have experienced >= 1 OHE episode within 30  days of enrollment (qualifying OHE) and were followed for recurrence (on-study OHE). RESULTS: Two hundred and sixty-five @entity1 were enrolled at 30 sites and followed for up to 9  months (mean 72  days). Seventy-two @entity1 experienced 122 on-study episodes; with 72, 23, and 13 having >= 1, >= 2, or >= 3 on-study episodes with median days to occurrence of the 1st, 2nd, and 3rd episode of 34, 19, and 11, respectively. The most frequently recorded OHE manifestations included @entity911 (78  %), change in @entity1032 (57  %), disorientation (48  %), lethargy (46  %), and @entity2358 (45  %). West Haven grade was used inconsistently and recorded for only 28  % of episodes. Most qualifying and on-study episodes occurred on @entity1761 (60 and 82  %, respectively) and were associated with hospitalization (68 and 85  %, respectively). Twenty-three @entity1 experienced >= 2 on-study episodes within 2  months of enrollment on average (median 45  days) and accounted for 60  % of on-study episodes. CONCLUSIONS: In this prospective study, OHE's most commonly recorded presenting manifestations included @entity911 , altered @entity1032 , disorientation, lethargy, and @entity2358 . As reflected by frequent recurrence and hospitalizations, OHE, particularly the approximately 10  % of "high-resource-utilizing" @entity1 with frequent recurrence, continues to pose a major unmet medical need and health-care burden despite the use of @entity1761 .

Prospective Multicenter Observational Study of Overt XXXX .

@entity1 :: ('9606', 'Species') :: ['patients'] @entity1032 :: ('MESH:D008607', 'Disease') :: ['mental status'] @entity82 :: ('MESH:D005355', 'Disease') :: ['cirrhosis'] @entity2358 :: ('MESH:D020820', 'Disease') :: ['asterixis'] @entity1761 :: ('MESH:C042734', 'Chemical') :: ['rifaximin'] @entity911 :: ('MESH:D003221', 'Disease') :: ['confusion'] @entity99 :: ('MESH:D056486', 'Disease') :: ['hepatic encephalopathy']
@entity99 :: (MESH:D056486,Disease) :: ['Hepatic Encephalopathy']
